53 ERA Poster printing financially sponsored by: Introduction Anaemia treatment optimization still remains a priority in haemodialysis (HD) patients due to its both health and financial implications. The use of a more aggressive iron therapy has been proposed in order to reduce ESA consumption but high intravenous iron therapy dosing is also associated with complications, and its long-term safety is not adequately known. Objectives To assess Hb levels and ESA consumption with small iron doses per treatment (SIDT). To compare Hb results in clinics with SIDT versus weekly iron administration (WIA). Methods The methodology used was observational and retrospective. Patient data were recorded in a database from which anonymous data were extracted, refined, and examined regarding all patients, who underwent OL-HDF for 12 months, from January 2013 to December 2013. The selected participants had to meet the following inclusion criteria: patients with a dialysis vintage of at least 3 months, receiving ESA therapy at least once a month and IV iron therapy. We compared the use of ESA and iron and Hb results in 34 clinics on the total of 4,436 patients. In this analysis it was considered 8 clinics with SIDT (1,385 patients) versus weekly iron administration in the others (3,051 patients). We used the Wilcoxon-Mann-Whitney test. Results Average ESA dose was 1.53±1,55 vs 1.58±1.54 µg/kg/month; p<0.001 Average iron dose was 2.81±2.16 vs 3.16±2.34 mg/kg/month; p<0.001 Average Ferritin was 552±298.50 vs 573.94±328.73; p=0.017 The clinics with small iron doses per treatment, obtained higher average Hb values (7.32±1.104 g/dL) per unit of ESA (µg/kg/month) as compared to the clinics with weekly iron administration (7.21±0.073 g/dL), despite the non-statistical significance (p=0.827). See Graph 1. The clinics with small iron doses per treatment, obtained better average Hb results (3.96±0.629 g/dL) per unit of iron (mg/kg/month) as compared to the clinics with weekly iron administration (3.45±0.655 g/dL). This result was statistically significant (p=0.058, p<0.10). See Graph 2. Conclusion Our study showed that the haemodialysis centres in which the patients were submitted to intravenous small iron doses per dialysis session (20-50mg), obtained higher hemoglobin values with less consumption of iron and erythropoiesis stimulating agents, when compared to the centres in which patients received a single iron dose per week (100mg). References 1. Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P: Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 2004, 38:405–416. 2. Prabhu MV, Nayak A, Sridhar G et al. Maximizing the erythropoietin response: iron strategies. Contrib Nephrol 2012; 178: 95–99. 3. Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP: Predictors of hyporesponsiveness to erythropoiesis stimulating agents agents in chronic hemodialysis patients. Am J Kidney Dis 2009; 53(5): 823–834. 4. Locatelli F, Manzoni C, Del Vecchio L et al. Management of anaemia by convective treatments. Contrib Nephrol, Basel Karger 2011; 168: 162–172. 5. Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, Hörl W, London G, Vanholder R, Van Biesen W, on behalf of the ERA-EDTA ERBP Advisory Board: Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013, 28: 1346–1359 Comparison of patient haemoglobin outcomes with weekly iron administration vs per session iron administration in adult haemodialysis patients Joao Fazendeiro Matos 1 , Ricardo Peralta 1 , Carla Felix 1 , Bruno Pinto 1 , Ilidio Rodrigues 2 , Carlos Oliveira 3 , Anibal Ferreira 4,5 , Pedro Ponce 6 1 Fresenius Medical Care, NephroCare Portugal, Porto, Portugal; 2 Fresenius Medical Care, NephroCare Barreiro, Barreiro, Portugal; 3 Fresenius Medical Care, NephroCare Almada, Almada, Portugal; 4 Fresenius Medical Care, NephroCare VFXira, VFXira, Portugal; 5 Nova Medical School, Medicine, Lisboa, Portugal; 6 Fresenius Medical Care, NephroCare Portugal, Lisboa, Portugal. Contact author: jfazendeiro.matos@fmc-ag.com Average age was 69±14 years (range: 17 to 100), 58.9% were men. Evaluation of 665,712 treatments revealed the following results between the two groups (SIDT vs WIA): 1823 41% 2613 59% Gender Female Male 34 Dialysis Centres 4,436 patients 1,385 patients SIDT 3,051 patients WIA 665,712 treatments analysed Small iron doses per treatment Weekly iron administration Hemoglobin/ESA SIDT WIA Hemoglobin/Iron SIDT WIA Graph 1 Graph 2 Average SIDT WIA p ESA dose (µg/kg/month) 1.53±1,55 1.58±1.54 p<0.001 Iron dose (mg/kg/month) 2.81±2.16 3.16±2.34 p<0.001 Ferritin (mg/L) 552±298.50 573.94±328.73 p=0.017 53 rd ERA/EDTA Congress – Vienna, Austria – May 21 st -24 th , 2016 547--SP Joao Fazendeiro DOI: 10.3252/pso.eu.53era.2016 Dialysis. Anaemia.